Foghorn Therapeutics Inc. Financing Cash Flow
Foghorn Therapeutics Inc. (FHTX) reported Financing Cash Flow of $49.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$22.00K, a 108.66% decline year-over-year.
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $49.77M, a 35707.19% increase year-over-year.
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $581.00K, a 14425.00% increase year-over-year.
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $49.00K, a 95.34% decline year-over-year.
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $1.02M, a 99.03% decline from fiscal 2024.
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $105.43M, a 5829.58% increase from fiscal 2023.
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.78M, a 0.85% increase from fiscal 2022.
- Foghorn Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.76M, a 92.14% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $49.75M 10-Q · filed 2026-08-06 | $50.33M derived: sum of 3 quarters · filed 2026-08-06 | $50.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $49.77M 10-Q · filed 2026-05-07 | $50.35M derived: sum of 2 quarters · filed 2026-05-07 | $50.40M derived: sum of 3 quarters · filed 2026-05-07 | $50.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $630.00K derived: sum of 2 quarters · filed 2026-03-11 | $884.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.02M 10-K · filed 2026-03-11 |
| 2025-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $303.00K derived: sum of 2 quarters · filed 2026-08-06 | $442.00K 10-Q · filed 2025-11-05 | $446.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $254.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $393.00K 10-Q · filed 2026-08-06 | $397.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $139.00K 10-Q · filed 2026-05-07 | $143.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.19M derived: sum of 3 quarters · filed 2026-05-07 | $104.40M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.05M derived: sum of 2 quarters · filed 2026-03-11 | $104.26M derived: sum of 3 quarters · filed 2026-03-11 | $105.43M 10-K · filed 2026-03-11 |
| 2024-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $104.26M derived: sum of 2 quarters · filed 2025-11-05 | $105.42M 10-Q · filed 2025-11-05 | $105.61M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $103.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $104.37M 10-Q · filed 2025-08-05 | $104.56M derived: sum of 3 quarters · filed 2025-08-05 | $105.95M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-14 | $1.35M derived: sum of 2 quarters · filed 2025-05-14 | $2.74M derived: sum of 3 quarters · filed 2025-05-14 | $2.84M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.57M derived: sum of 2 quarters · filed 2025-03-06 | $1.68M derived: sum of 3 quarters · filed 2025-03-06 | $1.78M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.49M derived: sum of 2 quarters · filed 2024-11-04 | $1.59M 10-Q · filed 2024-11-04 | $1.61M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $205.00K 10-Q · filed 2024-08-08 | $221.00K derived: sum of 3 quarters · filed 2024-08-08 | $554.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $102.00K 10-Q · filed 2024-05-06 | $118.00K derived: sum of 2 quarters · filed 2024-05-06 | $451.00K derived: sum of 3 quarters · filed 2024-05-06 | $1.48M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $349.00K derived: sum of 2 quarters · filed 2024-03-07 | $1.38M derived: sum of 3 quarters · filed 2024-03-07 | $1.76M 10-K · filed 2024-03-07 |
| 2022-09-30 | $333.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.36M derived: sum of 2 quarters · filed 2023-11-02 | $1.75M 10-Q · filed 2023-11-02 | $23.49M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.41M 10-Q · filed 2023-08-04 | $23.15M derived: sum of 3 quarters · filed 2023-08-04 | $23.66M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $384.00K 10-Q · filed 2023-05-08 | $22.12M derived: sum of 2 quarters · filed 2023-05-08 | $22.63M derived: sum of 3 quarters · filed 2023-05-08 | $22.74M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $21.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $22.25M derived: sum of 2 quarters · filed 2023-03-09 | $22.36M derived: sum of 3 quarters · filed 2023-03-09 | $22.42M 10-K · filed 2023-03-09 |
| 2021-09-30 | $505.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $616.00K derived: sum of 2 quarters · filed 2022-11-08 | $678.00K 10-Q · filed 2022-11-08 | $129.19M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $173.00K 10-Q · filed 2022-08-09 | $128.68M derived: sum of 3 quarters · filed 2022-08-09 | $169.44M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $62.00K 10-Q · filed 2022-05-09 | $128.57M derived: sum of 2 quarters · filed 2022-08-09 | $169.32M derived: sum of 3 quarters · filed 2022-08-09 | $217.29M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $128.51M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $169.26M derived: sum of 2 quarters · filed 2022-08-09 | $217.23M derived: sum of 3 quarters · filed 2022-08-09 | $217.47M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $40.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $88.72M derived: sum of 2 quarters · filed 2021-11-09 | $88.96M 10-Q · filed 2021-11-09 | $97.46M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $47.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $48.21M 10-Q · filed 2021-08-10 | $56.71M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | $247.00K 10-Q · filed 2021-05-11 | $8.75M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $23.97M 10-K · filed 2021-03-18 | ||
| 2019-09-30 | $15.47M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |